Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2015-04-08 Declaration of Voting R…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Information relating to the total number of voting rights and shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is titled 'Monthly information regarding the total number of voting rights and total number of shares of the Company' and explicitly references Article 223-16 of the AMF General Regulations. It provides a monthly update on the total number of shares and voting rights as of March 31, 2015. This type of periodic disclosure regarding share capital structure and voting rights does not fit neatly into the primary financial report categories (10-K, IR, ER). It is a specific regulatory disclosure concerning share capital/voting rights, which is often categorized under general regulatory announcements or specific capital structure updates. Given the options, it is most closely related to updates on share capital structure, but since it is a specific, recurring regulatory disclosure about voting rights, and not a general capital change (SHA) or a director's dealing (DIRS), the most appropriate general regulatory category is RNS, as it is a mandatory regulatory filing that doesn't fit a more specific category like DIV or DVA (which is for results of a vote, not the current count). However, upon reviewing the definitions, none perfectly capture a 'Total Voting Rights' monthly update. Since it details the total number of shares and voting rights, it is a fundamental disclosure about the company's capital structure. If 'SHA' (Share Issue/Capital Change) is interpreted broadly to include ongoing reporting on the capital base, it might fit, but RNS is the safest fallback for mandatory, non-financial periodic disclosures. Given the nature of the data (total shares and voting rights), it is a specific regulatory filing. I will classify it as RNS (Regulatory Filings) as the best fit among the provided codes for a mandatory, non-financial, periodic regulatory disclosure.
2015-04-08 English
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated April 8, 2015, announcing a joint research collaboration agreement between Ipsen and Hannover Medical School regarding recombinant botulinum neurotoxins. It details the scope, objectives, and parties involved in the research program. This type of announcement, which details strategic partnerships, R&D activities, and scientific developments rather than routine financial results (like 10-K, ER, or IR), typically falls under general corporate news or investor relations material. Since there is no specific category for 'Research Collaboration Announcement' and it is not a formal regulatory filing like a 10-K or a specific financial report, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck, but given the press release format, RNS is the most appropriate fallback for significant, non-standard corporate news that isn't explicitly covered elsewhere. It is not an Earnings Release (ER), Interim Report (IR), or a formal Audit Report (AR). Given the content focuses on R&D strategy and partnership, it is a significant corporate update.
2015-04-08 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated April 8, 2015, announcing a joint research collaboration between Ipsen and Hannover Medical School regarding recombinant botulinum neurotoxins. It details the scope, duration (thirty months), financial terms (milestone payments and royalties), and includes quotes from executives and researchers. This type of announcement, detailing a strategic partnership, research development, and associated financial arrangements, does not fit the definitions for standard financial reports (10-K, IR, ER, MRQ) or specific corporate actions (DIV, SHA, POS). It is a general corporate announcement regarding strategic development and partnership. Since it is not a report announcement (RPA/RNS) but the substance of the announcement itself, and it relates to strategic R&D collaboration, it is best classified as a general Regulatory Filing (RNS) as it is a public disclosure of a material event, or potentially a general Investor Relations document, but RNS serves as the best fit for non-standard, material press releases that aren't explicitly covered by other codes like M&A (TAR) or Capital Change (CAP). Given the context of a press release announcing a strategic R&D deal, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback category for this type of corporate news release.
2015-04-08 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is titled with headings like "COMMUNIQUÉ DE PRESSE" (Press Release) and details a specific corporate event: the inauguration of a new R&D center in Cambridge, MA, and an associated scientific symposium. It includes quotes from the CEO, the French Ambassador, and local life science leaders. The content is informational, announcing a strategic business development and an event, rather than presenting periodic financial results (like 10-K, IR, ER) or specific regulatory filings (like DIRS, DIV, DEF 14A). Since it is a general announcement about corporate activity and strategy, and does not fit into the specific categories like M&A (TAR) or Capital Change (CAP), it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but given the press release format announcing news, RNS is the most appropriate general category for non-standard announcements, or potentially a general announcement that might accompany an Investor Presentation, but the core nature is a press release about expansion. Given the options, RNS serves as the best fit for a general corporate news announcement that isn't a core financial report or specific transaction notice. However, since it is a detailed announcement about business strategy and expansion, it shares characteristics with investor relations material. Given the structure and content (announcing a major strategic move and an event), it is a general corporate announcement. RNS is the fallback for general regulatory announcements. If the document were an Investor Presentation (IP), it would typically be structured more like slides or a formal presentation deck. This reads purely as a press release. I will classify it as RNS (Regulatory Filings) as the best fit for a general corporate news release not covered by other specific codes.
2015-04-01 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 90% confidence The document is a press release dated April 1st, 2015, announcing the inauguration of Ipsen's new R&D center in Cambridge, MA, and a related scientific symposium. It contains company updates, strategic information, quotes from executives and external stakeholders, and details about R&D focus areas and financial performance highlights from 2014 (sales figures). This content is characteristic of a general corporate announcement or news release that doesn't fit the strict definitions of a formal regulatory filing (like 10-K, IR, ER) or a specific shareholder communication (like DEF 14A, DVA). Since it is a general announcement about corporate activity and strategy, and it is not explicitly announcing the publication of a formal report (which would suggest RPA/RNS), the most appropriate general category for this type of corporate news release is 'Regulatory Filings' (RNS) as a catch-all for non-standard announcements, or potentially 'Investor Presentation' (IP) if it were structured as a presentation, but given the format, RNS is the best fit among the provided options for a general corporate update/news release.
2015-04-01 English
Document availability communications / Methods of making financial reports or updated prospectuses available
Report Publication Announcement Classification · 98% confidence The document is a short announcement titled "The Ipsen Group publishes its 2014 Registration Document." It explicitly states that the Registration Document has been filed with the AMF and provides links where the full document can be accessed. According to Rule #2 (The 'MENU VS MEAL' Rule), when a document is short and announces the publication of a larger report, it should be classified as a Report Publication Announcement (RPA). The document is only 3402 characters long and its primary function is to announce the availability of the 2014 Registration Document, which incorporates the Annual Financial Report.
2015-03-31 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.